Clinical trials: Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This randomized pilot phase I trial studies the side effects of human lysozyme goat milk in treating patients with blood cancer undergoing a donor stem cell transplant.
- Trial name
- NCT03531281
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide
- Where
- United States
- Sponsor
- City of Hope Medical Center
Breast Cancer, Iron Overload
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant.
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma
- Trial name
- NCT00602446
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Iron Overload
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
This study has been designed to establish the efficacy and safety of deferasirox in patients with iron overload from 6 to 18 months after allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT01335035
- Testing
- deferasirox
- Where
- 9 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation
Seventy-five percent of patients treated with hematopoietic stem cell transplants survive one-year post-transplantation. However, this intensive treatment is associated with prolonged hospitalizations and significant…
- Trial name
- PrepAllo (NCT07341698)
- Testing
- Resistance training, Nutritional Support, Usual care
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced. Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection.
- Trial name
- NCT05789615
- Testing
- Letermovir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor
Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
- Trial name
- NCT04160390
- Testing
- Biospecimen Collection-Blood, Biospecimen Collection-Stool
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Transplantation Infection, Kidney Transplant; Complications
Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients
This is a pilot study designed to investigate the alterations in the gut microbiome that occur during the course of kidney transplantation, liver transplantation, allogeneic hematopoietic stem cells and mesenchymal stem cells…
- Conditions
- Transplantation Infection, Kidney Transplant; Complications, Stem Cell Transplant Complications, Liver Transplant; Complications
- Trial name
- NCT04281797
- Testing
- Intestinal microbiome new generation sequencing
- Where
- Belarus
- Volunteers
- 90 people
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Hematopoietic Stem Cell Transplantation
Physical Fitness of Allogeneic Stem Cell Transplant
Hematopoietic stem cell transplantation is a treatment used to restore blood cell function in diseases of myeloid and lymphoid origin, which can be malignant or non-malignant.
- Trial name
- NCT07049536
- Testing
- Assessment Group, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Istinye University
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Hypogammaglobulinemia
Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients
Tolerability of home subcutaneous immunoglobulin (ScIG) for replacement therapy for hypogammaglobulinemia in allogeneic HCT patients.
- Trial name
- ScIGalloHCT (NCT03401268)
- Testing
- subcutaneous immunoglobulin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Malignancy, Metabolic Disease
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
This study will describe the pharmacokinetic disposition of biologically active rabbit anti-thymocyte globulin (rATG) after a consistent dose of 7.5 mg/kg/course given as part of the conditioning regimen in children undergoing…
- Conditions
- Malignancy, Metabolic Disease, Genetic Disorder
- Trial name
- NCT01135537
- Testing
- Thymoglobulin (rATG)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- The Hospital for Sick Children
Kidney Transplant, Renal Transplant Recipients
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
This study will evaluate the safety and feasibility of treatment involving a single infusion of donor-derived regulatory dendritic cells (DCreg) in first time, living donor renal transplant recipients.
- Trial name
- RTB-006 (NCT03726307)
- Testing
- DCreg: 0.5 million cells/kg+SOC, DCreg: 1.2 million cells/kg+SOC, DCreg:2.5 to 5.0 million cells/kg+SOC
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Angus W. Thomson PhD DSc
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
- Trial name
- NCT03925532
- Testing
- Denosumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Leukemia, Relapse
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance after allo-HSCT in FLT3-negative acute leukemia patients.
- Conditions
- Acute Leukemia, Relapse, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04674345
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
VABu Conditioning in Elderly AML HSCT
This is an open-label, multi-center, single-arm clinical study evaluating the efficacy and safety of the VABu conditioning regimen in elderly patients (≥60 years) with acute myeloid leukemia (AML) undergoing allogeneic…
- Trial name
- NCT07583888
- Testing
- VaBU
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant.
- Trial name
- NCT03023631
- Testing
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center